L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: A double-blind, placebo-controlled, randomized trial

Journal of Psychiatric Research

Volumn 59, Issue , 2014, Pages 125-131

  Zeinoddini, Atefeh ^a   Ahadi, Morvarid ^a   Farokhnia, Mehdi ^a   Rezaei, Farzin ^b   Tabrizi, Mina ^c   Akhondzadeh, Shahin ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KURDISTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Clinical trial; L lysine; Nitric oxide; PANSS; Schizophrenia

Indexed keywords

LYSINE; PLACEBO; RISPERIDONE; NEUROLEPTIC AGENT;

ABDOMINAL PAIN; ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM RATING SCALE; FEMALE; FOLLOW UP; HAMILTON SCALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; RASH; SCHIZOPHRENIA; VOMITING; XEROSTOMIA; CHRONIC DISEASE; COMPLICATION; DEPRESSION; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYSINE; MALE; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84908361172     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2014.08.016     Document Type: Article

References (40)

1. Akbarian S., Bunney W.E., Potkin S.G., Wigal S.B., Hagman J.O., Sandman C.A., et al. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry 1993, 50:169-177.
2. Akbarian S., Vinuela A., Kim J.J., Potkin S.G., Bunney W.E., Jones E.G. Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Arch Gen Psychiatry 1993, 50:178-187.
3. Baba H., Suzuki T., Arai H., Emson P.C. Expression of nNOS and soluble guanylate cyclase in schizophrenic brain. Neuroreport 2004, 15:677-680.
4. Carter B.W., Chicoine L.G., Nelin L.D. l-lysine decreases nitric oxide production and increases vascular resistance in lungs isolated from lipopolysaccharide-treated neonatal pigs. Pediatr Res 2004, 55:979-987.
5. Chouinard G., Margolese H.C. Manual for the extrapyramidal symptom rating scale (ESRS). Schizophr Res 2005, 76:247-265.
6. Deutsch S.I., Rosse R.B., Schwartz B.L., Fay-McCarthy M., Rosenberg P.B., Fearing K. Methylene blue adjuvant therapy of schizophrenia. Clin Neuropharmacol 1997, 20:357-363.
7. Djordjevic V.V., Stojanovic I., Stankovic-Ferlez D., Ristic T., Lazarevic D., Cosic V., et al. Plasma nitrite/nitrate concentrations in patients with schizophrenia. Clin Chem Lab Med 2010, 48:89-94.
8. Farokhnia M., Azarkolah A., Adinehfar F., Khodaie-Ardakani M.R., Hosseini S.M., Yekehtaz H., et al. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol 2013, 36:185-192.
9. Farokhnia M., Sabzabadi M., Pourmahmoud H., Khodaie-Ardakani M.R., Hosseini S.M., Yekehtaz H., et al. Adouble-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia. Psychopharmacol Berl 2014, 231:533-542.
10. Finnerty N. Electrochemical sensors: in-vitro and in-vivo analysis of brain nitric oxide and regional cerebral blood flow 2008, PhD thesis, National University of Ireland, Department of Chemistry, Maynooth.
11. Flodin N.W. The metabolic roles, pharmacology, and toxicology of lysine. JAm Coll Nutr 1997, 16:7-21.
12. Griffith R.S., Walsh D.E., Myrmel K.H., Thompson R.W., Behforooz A. Success of l-lysine therapy in frequently recurrent herpes simplex infection. Treatment and prophylaxis. Dermatologica 1987, 175:183-190.
13. Hamilton M. Arating scale for depression. JNeurol Neurosurg Psychiatry 1960, 23:56-62.
14. Hanson E., Healey K., Wolf D., Kohler C. Assessment of pharmacotherapy for negative symptoms of schizophrenia. Curr Psychiatry Rep 2010, 12:563-571.
15. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
16. Khodaie-Ardakani M.R., Mirshafiee O., Farokhnia M., Tajdini M., Hosseini S.M., Modabbernia A., et al. Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. Psychiatry Res 2014.
17. Klamer D., Engel J.A., Svensson L. The nitric oxide synthase inhibitor, L-NAME, block phencyclidine-induced disruption of prepulse inhibition in mice. Psychopharmacol Berl 2001, 156:182-186.
18. Klamer D., Engel J.A., Svensson L. Phencyclidine-induced behaviour in mice prevented by methylene blue. Basic Clin Pharmacol Toxicol 2004, 94:65-72.
19. Lee B.H., Kim Y.K. Reduced plasma nitric oxide metabolites before and after antipsychotic treatment in patients with schizophrenia compared to controls. Schizophr Res 2008, 104:36-43.
20. Leon A.C. Multiplicity-adjusted sample size requirements: a strategy to maintain statistical power with Bonferroni adjustments. JClin Psychiatry 2004, 65:1511-1514.
21. Levkovitz Y., Mendlovich S., Riwkes S., Braw Y., Levkovitch-Verbin H., Gal G., et al. Adouble-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. JClin Psychiatry 2010, 71:138-149.
22. Lopes M.C., Cardoso S.A., Schousboe A., Carvalho A.P. Amino acids differentially inhibit the l-[3H]arginine transport and nitric oxide synthase in rat brain synaptosomes. Neurosci Lett 1994, 181:1-4.
23. Miyaoka T., Yasukawa R., Yasuda H., Hayashida M., Inagaki T., Horiguchi J. Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin Neuropharmacol 2008, 31:287-292.
24. Modabbernia A., Rezaei F., Salehi B., Jafarinia M., Ashrafi M., Tabrizi M., et al. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study. CNS Drugs 2013, 27:57-65.
25. Murphy B.P., Chung Y.C., Park T.W., McGorry P.D. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res 2006, 88:5-25.
26. Noroozian M., Ghasemi S., Hosseini S.M., Modabbernia A., Khodaie-Ardakani M.R., Mirshafiee O., et al. Aplacebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. Psychopharmacol Berl 2013, 228:595-602.
27. Palsson E., Fejgin K., Wass C., Engel J.A., Svensson L., Klamer D. The amino acid l-lysine blocks the disruptive effect of phencyclidine on prepulse inhibition in mice. Psychopharmacology 2007, 192:9-15.
28. Palsson E., Fejgin K., Wass C., Klamer D. Agmatine attenuates the disruptive effects of phencyclidine on prepulse inhibition. Eur J Pharmacol 2008, 590:212-216.
29. Ramirez J., Garnica R., Boll M.C., Montes S., Rios C. Low concentration of nitrite and nitrate in the cerebrospinal fluid from schizophrenic patients: a pilot study. Schizophr Res 2004, 68:357-361.
30. Reis D.J., Regunathan S. Is agmatine a novel neurotransmitter in brain?. Trends Pharmacol Sci 2000, 21:187-193.
31. Rezaei F., Mohammad-Karimi M., Seddighi S., Modabbernia A., Ashrafi M., Salehi B., et al. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. JClin Psychopharmacol 2013, 33:336-342.
32. Shinkai T., Ohmori O., Hori H., Nakamura J. Allelic association of the neuronal nitric oxide synthase (NOS1) gene with schizophrenia. Mol Psychiatry 2002, 7:560-563.
33. Singh M., Rao D.M., Pande S., Battu S., Mahalakshmi K., Ramesh M. Medicinal uses of l-lysine: past and future. Int J Res Pharm Sci 2011, 2:637-642.
34. Singh S.P., Singh V., Kar N., Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry 2010, 197:174-179.
35. Taneli F., Pirildar S., Akdeniz F., Uyanik B.S., Ari Z. Serum nitric oxide metabolite levels and the effect of antipsychotic therapy in schizophrenia. Arch Med Res 2004, 35:401-405.
36. Wass C., Klamer D., Katsarogiannis E., Palsson E., Svensson L., Fejgin K., et al. l-lysine as adjunctive treatment in patients with schizophrenia: a single-blinded, randomized, cross-over pilot study. BMC Med 2011, 9:40.
37. White M.F., Gazzola G.C., Christensen H.N. Cationic amino acid transport into cultured animal cells. I. Influx into cultured human fibroblasts. JBiol Chem 1982, 257:4443-4449.
38. Wiesinger H. Arginine metabolism and the synthesis of nitric oxide in the nervous system. Prog Neurobiol 2001, 64:365-391.
39. Wu F., Cholewa B., Mattson D.L. Characterization of l-arginine transporters in rat renal inner medullary collecting duct. Am J Physiol Regul Integr Comp Physiol 2000, 278:R1506-R1512.
40. Yilmaz N., Herken H., Cicek H.K., Celik A., Yurekli M., Akyol O. Increased levels of nitric oxide, cortisol and adrenomedullin in patients with chronic schizophrenia. Med Princ Pract 2007, 16:137-141.